Back
GLINT: GlucoCEST in neoplastic tumours at 3T - first-in-man studies of GlucoCEST in glioma patients
{Purpose: Dynamic glucose enhanced (DGE) CEST imaging has almost only been shown at ultra-high field (UHF) due to low effect size. First results in brain tumour patients of a DGE CEST method with fast 3D imaging developed for clinical field strength are shown herein. Methods and Materials: CEST saturated images at different frequency offsets were acquired at 160 time points before, during and after a glucose injection (0.3 mg/kg) with 6.3s temporal resolution (Total: 16:45 min) to detect accumulation in the brain. Two glioblastoma (IDH wild-type, unmethylated MGMT promoter) patients (1: male, 70y, 2: female, 75y) and 3 healthy controls were scanned at a clinical 3T System. DGE contrast images were analysed by subtracting each image from a pre-injection baseline image: $\Delta$DGE(t)\textequalsDGEbaseline - DGE(t). Results: In the high-grade glioma (1), glucose uptake in the Gadolinium enhancing region could be detected approximately 4 minutes after injection with a maximum increase of $\Delta$DGE\textequals0.51$\pm$0.078, whereas a contralateral white matter ROI was barely affected ($\Delta$DGE\textequals0.07$\pm$0.085) at the same time point. The second glioma (2), with the same histology and grading, showed very little gadolinium enhancement as well as no significant detectable DGE effect. Healthy controls did not show any significant DGE contrast. Conclusion: We demonstrated that stable dynamic glucose enhanced imaging can be accomplished at clinical field strength using optimized saturation and readout parameters. First results are promising, and indicate that glucoCEST corresponds more to the disruptions of the blood-brain-barrier with Gadolinium uptake than to the molecular tumour profile or tumour grading.}
@misc{item_3032334, title = {{GLINT: GlucoCEST in neoplastic tumours at 3T - first-in-man studies of GlucoCEST in glioma patients}}, journal = {{Insights into Imaging}}, abstract = {{Purpose: Dynamic glucose enhanced (DGE) CEST imaging has almost only been shown at ultra-high field (UHF) due to low effect size. First results in brain tumour patients of a DGE CEST method with fast 3D imaging developed for clinical field strength are shown herein. Methods and Materials: CEST saturated images at different frequency offsets were acquired at 160 time points before, during and after a glucose injection (0.3 mg/kg) with 6.3s temporal resolution (Total: 16:45 min) to detect accumulation in the brain. Two glioblastoma (IDH wild-type, unmethylated MGMT promoter) patients (1: male, 70y, 2: female, 75y) and 3 healthy controls were scanned at a clinical 3T System. DGE contrast images were analysed by subtracting each image from a pre-injection baseline image: $\Delta$DGE(t)\textequalsDGEbaseline - DGE(t). Results: In the high-grade glioma (1), glucose uptake in the Gadolinium enhancing region could be detected approximately 4 minutes after injection with a maximum increase of $\Delta$DGE\textequals0.51$\pm$0.078, whereas a contralateral white matter ROI was barely affected ($\Delta$DGE\textequals0.07$\pm$0.085) at the same time point. The second glioma (2), with the same histology and grading, showed very little gadolinium enhancement as well as no significant detectable DGE effect. Healthy controls did not show any significant DGE contrast. Conclusion: We demonstrated that stable dynamic glucose enhanced imaging can be accomplished at clinical field strength using optimized saturation and readout parameters. First results are promising, and indicate that glucoCEST corresponds more to the disruptions of the blood-brain-barrier with Gadolinium uptake than to the molecular tumour profile or tumour grading.}}, volume = {10}, pages = {S206}, year = {2019}, slug = {item_3032334}, author = {Lindig, T and Zaiss, M and Herz, K and Deshmane, A and Bender, B and Golay, X and Scheffler, K} }